Elutia Inc. (ELUT)
| Market Cap | 42.78M |
| Revenue (ttm) | 12.29M |
| Net Income (ttm) | 53.38M |
| Shares Out | 42.78M |
| EPS (ttm) | 0.87 |
| PE Ratio | 1.16 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,425 |
| Open | 1.040 |
| Previous Close | 1.020 |
| Day's Range | 1.000 - 1.050 |
| 52-Week Range | 0.500 - 2.640 |
| Beta | 0.71 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+500.0%) |
| Earnings Date | May 8, 2026 |
About ELUT
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac pat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ELUT stock is "Strong Buy" and the 12-month stock price target is $6.0.
News
Elutia Transcript: Sidoti March Small-Cap Virtual Conference
A new drug-eluting biologic for breast reconstruction aims to address a $1.5B market with high infection rates by delivering antibiotics directly at the surgical site. FDA approval for the base matrix is expected this year, with the drug-eluting version targeted for next year.
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Ch...
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity a...
Elutia Earnings Call Transcript: Q4 2025
Revenue grew 16% year-over-year to $3.3M with improved gross margins and reduced net loss. Strategic sale of BioEnvelope enabled debt repayment and a strong cash position, supporting the focus on NXT-41x for the large breast reconstruction market.
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year...
Elutia Regains Compliance with Nasdaq Listing Requirements
GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received not...
Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market
GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete ...
Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026
GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its ...
Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™
GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certifie...
Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones
Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia ...
Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery
Company to present Tuesday, January 13 th at 10:00 a.m. PT / 1:00 p.m.
Elutia Earnings Call Transcript: Q3 2025
Q3 2025 saw the $88M sale of the BioEnvelope business, strengthening the balance sheet and validating the technology. SimpliDerm and Cardiovascular segments showed sequential growth, with improved gross margins and reduced operating expenses. Sufficient cash runway supports NXT-41/41x development and commercialization.
Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development
- Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today a...
Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its ...
Elutia Transcript: LD Micro Main Event XIX Investor Conference
A proven drug-eluting biologics platform is being expanded from pacemaker applications to address high infection rates in breast reconstruction, targeting a $1.5 billion market with significant unmet need. The company is fully funded, with FDA filings for its next product expected in 2026.
Elutia to Present at the LD Micro Main Event XIX Conference on Tuesday, October 21
GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief ...
Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors
Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” ...
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., ...
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
- Findings highlight the potential of antibiotic-eluting bioenvelopes to transform cardiac implantable electronic device (CIED) pocket management -
Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million
- Transaction affirms the strength of Elutia's proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction -
Elutia Transcript: Cantor Global Healthcare Conference 2025
Management highlighted strong commercial traction for EluPro, a drug-eluting biologic for pacemakers, and plans to scale hospital adoption with Boston Scientific and GPO support. The pipeline includes NXT-41X for breast reconstruction, with approval expected in 2027. The company seeks non-dilutive capital and margin improvement.
Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange
GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selecte...
Elutia to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief ...
Elutia Earnings Call Transcript: Q2 2025
EluPro drove 49% sequential growth and now dominates BioEnvelope revenue, with strong hospital adoption and improved gross margins. NXT-41x breast reconstruction platform is on track for 2026–2027 launches, and legacy litigation is nearly resolved, reducing risk.
Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption
EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m.